CTRI/2021/02/031050招募中3 期
A Double Masked, Parallel Group, Randomized, Multicenter, Clinical Study to Compare Efficacy and Safety of Intas Ranibizumab with Lucentis® in Patients with Neovascular (Wet) Age Related Macular Degeneration (AMD).
Intas Pharmaceuticals Ltd Biopharma Division0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female participants aged 50 years or more at the time of screening.
- •2.Written informed consent at Screening must be obtained before any assessment is performed.
- •3.Willingness and ability to undertake all scheduled visits and assessments.
- •4.Newly diagnosed, treatment naïve patients with active subfoveal choroid neovascularization (CNV) lesion secondary to neovascular (wet) age-related macular degeneration (AMD) in the study eye at Screening and confirmed by the Central
- •Reading Center (CRC).
- •Note: Active CNV indicates the presence of leakage as evidenced by Fluorescein Angiography (FA) and intra- or subretinal fluid as evidenced by Optical Coherence Tomography (OCT) and must involve central subfield:
- •a.The area of CNV must be more than 50% of the total lesion area in the study eye confirmed
- •by the CRC, and
- •b.Total lesion area more than 9 Disc Areas (DA) in size (including blood, scars and neovascularization) as assessed by FA in the study eye.
- •c.All subtypes of nAMD CNV lesions are permissible (i.e., classic CNV, occult CNV,
- •or with some classic CNV component)
- •5.Good health as determined by past medical history, physical examination, vital signs,
- •and laboratory tests at screening.
- •6. BCVA of 20/40 to 20/200 (more then 73 and less then 34 ETDRS letter score) in the study eye using ETDRS chart at a distance of 4 meters at Screening and Baseline.
- •7.Fellow eye should not be expected to need any anti-VEGF treatment during the initial 8 weeks period of study participation.
排除标准
- •1. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, except for:
- •a.Women whose partners have been sterilized by vasectomy or other means.
- •b. Women using a highly effective method of birth control (i.e. one that results in a
- •less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some intrauterine devices (IUDs); periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods) is not acceptable).
- •2.Fertile males, defined as all males physiologically capable of conceiving offspring
- •a.the participant agrees to comply with two highly effective contraceptive methods comprising a barrier method (condom or occlusive cap plus spermicide) for the entire duration of the study, up to the Study Completion visit, and refrain from fathering a child for at least three (3) months following the last study drug administration.
- •3.Pregnant or nursing (lactating) women.
- •4.Central subfield of the study eye affected by fibrosis or geographic atrophy assessed by
- •color fundus photography and confirmed by the CRC at Screening.
- •5.Total area of scarring more than 50% of the total lesion in the study eye at Screening and confirmed by the CRC, in the study eye.
- •6.Subretinal hemorrhage in the study eye that involves the center of the fovea and/or the
- •size of the hemorrhage is either more than 50% of the total area of the lesion or more than 1-disc area in size at screening as confirmed by CRC.
- •7.Any infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis in either eye within 4 weeks prior to Baseline.
- •8.Any active intraocular inflammation (grade trace or above) in the study eye within 4
- •weeks prior to Baseline.
- •9.History of idiopathic or autoimmune associated uveitis in either eye.
- •10.CNV in either of the two eyes due to causes other than AMD such as DME, RVO,histoplasmosis, trauma, multifocal choroiditis, angioid streaks, history of choroidal rupture or pathologic myopia (spherical equivalent of â??6 diopters or more negative).
- •11.Prior interventions in the study eye
- •a.Prior Treatment with verteporfin, External
- •beam radiation treatment and Transpupillary thermotherapy in the study eye
- •b.Prior any intravitreal injection in the study eye.
- •c.Prior laser photocoagulation in the study eye
- •d.Prior vitrectomy in the study eye
- •e.Prior Glaucoma filtration surgery in the study eye
- •f.Prior Corneal Transplant in the study eye
- •g.Submacular surgery or any surgical intervention for AMD in study eye
- •h.Prior ocular surgery (including cataract) within the previous 3 months from baseline in the study eye.
- •12. Prior treatment with
- •a. Any prior anti-VEGF including Ranibizumab, Bevacizumab, Aflibercept and Pegaptanib (intravitreal or systemic) in either eye
- •b.Any prior intraocular use of corticosteroids in the study eye
- •c. Use of topical ocular corticosteroids in the study eye for 60 or more consecutive days within the 90 days period prior to Baseline
- •d.Use of systemic corticosteroids in the past 6 months.Note: Inhaled, nasal or dermal
- •steroids are permitted
- •13.Known hypersensitivity to ranibizumab or any of the components of study medication(histidine HCl,trehal
研究者
相似试验
进行中（未招募）
1 期
Clinical study to compare efficacy and safety of Intas Ranibizumab with Lucentis.eovascular (Wet) Age-Related Macular Degeneration (AMD)MedDRA version: 27.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2021-001970-41-CZIntas Pharmaceuticals Ltd.546
进行中（未招募）
1 期
Clinical study to compare efficacy and safety of Intas Ranibizumab with Lucentis.eovascular (Wet) Age-Related Macular Degeneration (AMD)MedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2021-001970-41-LVIntas Pharmaceuticals Ltd.546
进行中（未招募）
1 期
Clinical study to compare efficacy and safety of Intas Ranibizumab with Lucentis.EUCTR2021-001970-41-PLIntas Pharmaceuticals Ltd.546
进行中（未招募）
1 期
A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 µg/day and ASI-001B 0.2 µg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema - FAMEDiabetic Macular OedemaEUCTR2006-001035-22-PTAlimera Science Inc900
进行中（未招募）
1 期
A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 µg/day and ASI-001B 0.2 µg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema - FAMEEUCTR2006-001035-22-GBAlimera Science Inc900